Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02043665
Title Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Viralytics
Indications

urinary bladder cancer

lung non-small cell carcinoma

melanoma

prostate cancer

Therapies

Coxsackievirus A21

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.